Unión Europea - español - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - agentes antineoplásicos - poteligeo está indicado para el tratamiento de pacientes adultos con micosis fungoide (mf) o síndrome de sézary (ss) que han recibido al menos una antes de la terapia sistémica.

Chile - español - ISPC (Instituto de Salud Pública de Chile)

astrazeneca s.a. - ravulizumab - sin formulas

Unión Europea - español - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuria, paroxística - inmunosupresores selectivos - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Chile - español - ISPC (Instituto de Salud Pública de Chile)

astrazeneca s.a. - ravulizumab - sin formulas

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

astrazeneca peru s.a. - droguerÍa - ravulizumab - concentrado para solucion para perfusion - 300 mg/3 ml - por vial 1.00 u - - ravulizumab

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

astrazeneca peru s.a. - droguerÍa - ravulizumab - concentrado para solucion para perfusion - 1100 mg/11 ml - por vial 11.00 ml - - ravulizumab

Chile - español - ISPC (Instituto de Salud Pública de Chile)

astrazeneca s.a. - ravulizumab - sin formulas

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

alexion pharmaceuticals inc estados unidos - cada ml contiene: ravulizumab??.100 mg/ml - concentrado para solución para perfusión - cada ml contiene: ravulizumab??.100 mg/ml